The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $292,746 Cooperative Agreement to Tsrl, Inc. (doing business as Therapeutic Systems Research Laboratories) on July 10, 2024. The purpose of this award is to conduct a Phase 1 clinical trial to assess the pharmacokinetics, safety, and tolerance of a zanamivir transdermal system in healthy subjects. This research aims to develop an improved delivery method for the influenza drug zanamivir, which could potentially benefit the millions of people affected by annual influenza epidemics. Tsrl, Inc. is a pharmaceutical research and development company that specializes in infectious disease therapeutics and novel drug delivery systems.
Generated 1/28/25, 8:39 AM